Trends in thrombolytic use for ischemic stroke in the United States

Journal of Hospital Medicine

Volumn 5, Issue 7, 2010, Pages 406-409

  Fang, Margaret C ^a   Cutler, David M ^b,c   Rosen, Allison B ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD UNIVERSITY   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute stroke; Ischemic stroke; Outcomes measurement; Quality improvement; Thrombolysis; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL FEATURE; DEMOGRAPHY; DRUG USE; FEMALE; FIBRINOLYTIC THERAPY; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; UNITED STATES;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CONFIDENCE INTERVALS; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HEALTH STATUS INDICATORS; HUMANS; INPATIENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT DISCHARGE; QUALITY OF HEALTH CARE; RISK ASSESSMENT; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77956713424     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.689     Document Type: Article

References (26)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781-1787.
3. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rT-PA stroke trials. Lancet. 2004;363:768-774.
4. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study. Lancet. 2007;369:275-282.
5. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. JAMA. 2000;283:3102-3109.
6. Klijn CJ, Hankey GJ. Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol. 2003;2:698-701.
7. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115:e478-534.
8. The Joint Commission Primary Stroke Center Certification. Available at: http://www.jointcommission.org/CertificationPrograms/PrimaryStrokeCenters. Accessed February 2010.
9. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA. 2000;283:1151-1158.
10. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654-659.
11. Qureshi AI, Suri MF, Nasar A, et al. Thrombolysis for ischemic stroke in the united states: Data from National Hospital Discharge Survey 1999-2001. Neurosurgery. 2005;57:647-654; discussion 647-654.
12. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924-928.
13. US Department of Health and Human Services Public Health Service and National Center for Health Statistics. National Hospital Discharge Durvey 1991-2006. Multi-year public-use data file documentation.
14. Deyo R, Cherkin D, Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
15. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke. 1996;27:1760-1764.
16. Barber P, Zhang J, Demchuk A, Hill M, Buchan A. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001;57:1739-1740.
17. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61:346-350. (Pubitemid 38327350)
18. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:27-29.
19. Nadeau JO, Shi S, Fang J, et al. Tpa use for stroke in the registry of the Canadian stroke network. Can J Neurol Sci. 2005;32:433-439. (Pubitemid 41788901)
20. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke. 2001;32:1061-1068.
21. Saver JL, Gornbein J, Grotta J, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: Joint outcome table analysis of the ECASS 3 trial. Stroke. 2009;40:2433-2437.
22. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34:2847-2850. (Pubitemid 37517754)
23. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke. 1998;29:1544-1549.
24. Bateman BT, Schumacher HC, Boden-Albala B, et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the Nationwide Inpatient Sample 1999 to 2002. Stroke. 2006;37:440-446.
25. Zweifler RM, Brody ML, Graves GC, et al. Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology. 1998;50:501-503.
26. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001;58:2009-2013.